This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003; 17: 1448–1453.
Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele N et al. Significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004; 100: 116–121.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kantarjian, H., Cortes, J. Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. Leukemia 18, 650 (2004). https://doi.org/10.1038/sj.leu.2403277
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403277
This article is cited by
-
Predicting the response of CML patients to tyrosine kinase inhibitor therapy
Current Hematologic Malignancy Reports (2009)